Aspen Park Pharmaceuticals
2014
FOUNDED
M&A
STATUS
1-10
EMPLOYEES
M&A
LATEST DEAL TYPE
3
FINANCING ROUNDS
Description
Developer of novel therapies for premature ejaculation in men. The company focuses on the development and commercialization of novel therapies for men's health diseases and conditions, including male secondary hypogonadism, prostate cancer, and sexual dysfunction.
Website
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Therapeutic Devices
Other Industries
Managed Care
Clinics/Outpatient Services
Acquirer
Primary Office
- 944 Park Avenue
- New York, NY 10028
- United States
Aspen Park Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Aspen Park Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookAspen Park Pharmaceuticals Executive Team (2)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Harry Fisch | Co-Founder, Chairman & Chief Scientific Officer | ||
| Mitchell Steiner Ph.D | Co-Founder, President, Managing Director & Chief Executive Officer |
Aspen Park Pharmaceuticals Board Members (2)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 00000 000000000 | Aspen Park Pharmaceuticals | Board Member | 000 0000 | |
| 0000000 00000 | Self | Board Member | 000 0000 |